Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Hypertension, Pulmonary, Ventricular Dysfunction, Left

In brief

The aim of this study is to assess whether oral Riociguat affects the left ventricular contractility and relaxation in patients with pulmonary hypertension associated with left ventricular systolic dysfunction

Key facts

Study ID

NCT01065051

Run by

Bayer

People needed

1

Starts

2010-11-01

Expected to finish

2011-01-01

Last updated by the study team

2014-01-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female patients with symptomatic pulmonary hypertension due to left ventricular systolic dysfunction despite standard heart failure therapy

You may not qualify if…

• Types of pulmonary hypertension other than group 2.1 of Dana Point Classification

Where it is running

• Study site — Boston, Massachusetts, United States
• Study site — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.